nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—UGT1A1—Rifampicin—leprosy	0.184	0.342	CbGbCtD
Nilotinib—CYP2B6—Rifampicin—leprosy	0.0712	0.132	CbGbCtD
Nilotinib—CYP2C8—Rifampicin—leprosy	0.0539	0.1	CbGbCtD
Nilotinib—CYP2C8—Dapsone—leprosy	0.0445	0.0828	CbGbCtD
Nilotinib—CYP2C9—Thalidomide—leprosy	0.0388	0.0722	CbGbCtD
Nilotinib—CYP2C9—Rifampicin—leprosy	0.0376	0.07	CbGbCtD
Nilotinib—ABCB1—Rifampicin—leprosy	0.0365	0.0679	CbGbCtD
Nilotinib—CYP2C9—Dapsone—leprosy	0.0311	0.0577	CbGbCtD
Nilotinib—CYP3A4—Rifampicin—leprosy	0.0219	0.0407	CbGbCtD
Nilotinib—CYP3A4—Dapsone—leprosy	0.0181	0.0336	CbGbCtD
Nilotinib—Blood phosphorus decreased—Thalidomide—leprosy	0.00708	0.0414	CcSEcCtD
Nilotinib—MAPK8—skin epidermis—leprosy	0.00573	0.0414	CbGeAlD
Nilotinib—CA6—ear—leprosy	0.00557	0.0403	CbGeAlD
Nilotinib—CA3—ear—leprosy	0.00528	0.0382	CbGeAlD
Nilotinib—Swelling face—Dapsone—leprosy	0.00422	0.0247	CcSEcCtD
Nilotinib—EPHB3—nerve—leprosy	0.00403	0.0291	CbGeAlD
Nilotinib—MAPK8—blood vessel—leprosy	0.00384	0.0277	CbGeAlD
Nilotinib—Tumour lysis syndrome—Thalidomide—leprosy	0.0037	0.0217	CcSEcCtD
Nilotinib—Lipase increased—Thalidomide—leprosy	0.0035	0.0204	CcSEcCtD
Nilotinib—EPHA4—nerve—leprosy	0.00336	0.0243	CbGeAlD
Nilotinib—TIE1—blood vessel—leprosy	0.00333	0.024	CbGeAlD
Nilotinib—Electrolyte imbalance—Thalidomide—leprosy	0.00246	0.0144	CcSEcCtD
Nilotinib—EPHA8—eye—leprosy	0.00245	0.0177	CbGeAlD
Nilotinib—MAPK14—blood vessel—leprosy	0.00244	0.0176	CbGeAlD
Nilotinib—KIT—skin epidermis—leprosy	0.00239	0.0173	CbGeAlD
Nilotinib—Erythema nodosum—Thalidomide—leprosy	0.00238	0.0139	CcSEcCtD
Nilotinib—Dysaesthesia—Thalidomide—leprosy	0.00238	0.0139	CcSEcCtD
Nilotinib—Pericarditis—Thalidomide—leprosy	0.00238	0.0139	CcSEcCtD
Nilotinib—EPHB4—blood vessel—leprosy	0.00231	0.0167	CbGeAlD
Nilotinib—EPHA2—blood vessel—leprosy	0.00227	0.0164	CbGeAlD
Nilotinib—CDC42BPB—eye—leprosy	0.00226	0.0163	CbGeAlD
Nilotinib—TEK—blood vessel—leprosy	0.00221	0.016	CbGeAlD
Nilotinib—EPHA3—eye—leprosy	0.00214	0.0155	CbGeAlD
Nilotinib—MAPK8—eye—leprosy	0.00204	0.0148	CbGeAlD
Nilotinib—Transient ischaemic attack—Thalidomide—leprosy	0.00204	0.0119	CcSEcCtD
Nilotinib—Lymphopenia—Thalidomide—leprosy	0.00201	0.0117	CcSEcCtD
Nilotinib—Skin exfoliation—Dapsone—leprosy	0.00192	0.0112	CcSEcCtD
Nilotinib—CA1—nerve—leprosy	0.00186	0.0135	CbGeAlD
Nilotinib—MAPK8—skin of body—leprosy	0.00178	0.0128	CbGeAlD
Nilotinib—Blood lactate dehydrogenase increased—Thalidomide—leprosy	0.00177	0.0103	CcSEcCtD
Nilotinib—Gastric ulcer—Thalidomide—leprosy	0.00177	0.0103	CcSEcCtD
Nilotinib—Febrile neutropenia—Thalidomide—leprosy	0.00171	0.00999	CcSEcCtD
Nilotinib—Psoriasis—Thalidomide—leprosy	0.00164	0.00956	CcSEcCtD
Nilotinib—Hypomagnesaemia—Thalidomide—leprosy	0.00162	0.00946	CcSEcCtD
Nilotinib—Oral candidiasis—Thalidomide—leprosy	0.00162	0.00946	CcSEcCtD
Nilotinib—Hypothyroidism—Thalidomide—leprosy	0.0016	0.00936	CcSEcCtD
Nilotinib—KIT—blood vessel—leprosy	0.0016	0.0116	CbGeAlD
Nilotinib—PDGFRB—blood vessel—leprosy	0.00156	0.0113	CbGeAlD
Nilotinib—CDC42BPB—tendon—leprosy	0.00149	0.0108	CbGeAlD
Nilotinib—Hypercalcaemia—Thalidomide—leprosy	0.00148	0.00865	CcSEcCtD
Nilotinib—FRK—testis—leprosy	0.00147	0.0106	CbGeAlD
Nilotinib—CA4—nerve—leprosy	0.00146	0.0105	CbGeAlD
Nilotinib—Hepatomegaly—Thalidomide—leprosy	0.00145	0.00849	CcSEcCtD
Nilotinib—Thrombosis—Thalidomide—leprosy	0.00145	0.00849	CcSEcCtD
Nilotinib—Interstitial lung disease—Thalidomide—leprosy	0.00145	0.00849	CcSEcCtD
Nilotinib—Cyanosis—Thalidomide—leprosy	0.00145	0.00849	CcSEcCtD
Nilotinib—Hyperlipidaemia—Thalidomide—leprosy	0.00143	0.00834	CcSEcCtD
Nilotinib—EPHB2—nervous system—leprosy	0.00137	0.00993	CbGeAlD
Nilotinib—Cholestasis—Thalidomide—leprosy	0.00135	0.00791	CcSEcCtD
Nilotinib—MAPK8—tendon—leprosy	0.00135	0.00977	CbGeAlD
Nilotinib—EPHA8—testis—leprosy	0.00134	0.0097	CbGeAlD
Nilotinib—Pleural effusion—Thalidomide—leprosy	0.00134	0.00785	CcSEcCtD
Nilotinib—Skin ulcer—Thalidomide—leprosy	0.00132	0.00772	CcSEcCtD
Nilotinib—EPHA8—nervous system—leprosy	0.00132	0.00952	CbGeAlD
Nilotinib—Hyperaesthesia—Thalidomide—leprosy	0.00131	0.00766	CcSEcCtD
Nilotinib—Nasopharyngitis—Dapsone—leprosy	0.0013	0.00762	CcSEcCtD
Nilotinib—Muscular weakness—Dapsone—leprosy	0.00129	0.00752	CcSEcCtD
Nilotinib—Influenza—Dapsone—leprosy	0.00126	0.00737	CcSEcCtD
Nilotinib—Petechiae—Thalidomide—leprosy	0.00125	0.00731	CcSEcCtD
Nilotinib—MAPK11—testis—leprosy	0.00125	0.00902	CbGeAlD
Nilotinib—Endocrine disorder—Thalidomide—leprosy	0.00124	0.00725	CcSEcCtD
Nilotinib—CDC42BPB—testis—leprosy	0.00124	0.00895	CbGeAlD
Nilotinib—Pancreatitis—Dapsone—leprosy	0.00123	0.00722	CcSEcCtD
Nilotinib—MAP4K1—tendon—leprosy	0.00123	0.00888	CbGeAlD
Nilotinib—MAPK11—nervous system—leprosy	0.00122	0.00885	CbGeAlD
Nilotinib—CDC42BPB—nervous system—leprosy	0.00121	0.00878	CbGeAlD
Nilotinib—EPHA3—testis—leprosy	0.00117	0.00848	CbGeAlD
Nilotinib—EPHA3—nervous system—leprosy	0.00115	0.00833	CbGeAlD
Nilotinib—Photosensitivity reaction—Dapsone—leprosy	0.00115	0.00672	CcSEcCtD
Nilotinib—Musculoskeletal stiffness—Thalidomide—leprosy	0.00115	0.0067	CcSEcCtD
Nilotinib—Skin discolouration—Thalidomide—leprosy	0.00114	0.00665	CcSEcCtD
Nilotinib—Hyperbilirubinaemia—Thalidomide—leprosy	0.00113	0.00661	CcSEcCtD
Nilotinib—MAPK14—skin of body—leprosy	0.00113	0.00815	CbGeAlD
Nilotinib—BRAF—tendon—leprosy	0.00112	0.00812	CbGeAlD
Nilotinib—Hypocalcaemia—Thalidomide—leprosy	0.00112	0.00656	CcSEcCtD
Nilotinib—MAPK8—testis—leprosy	0.00112	0.00809	CbGeAlD
Nilotinib—EPHA6—testis—leprosy	0.00112	0.00809	CbGeAlD
Nilotinib—Herpes simplex—Thalidomide—leprosy	0.00112	0.00652	CcSEcCtD
Nilotinib—Hyperuricaemia—Thalidomide—leprosy	0.00111	0.00648	CcSEcCtD
Nilotinib—Neuropathy peripheral—Dapsone—leprosy	0.0011	0.00644	CcSEcCtD
Nilotinib—MAPK8—nervous system—leprosy	0.0011	0.00794	CbGeAlD
Nilotinib—EPHA6—nervous system—leprosy	0.0011	0.00794	CbGeAlD
Nilotinib—Leukocytosis—Thalidomide—leprosy	0.00109	0.00639	CcSEcCtD
Nilotinib—Hypercholesterolaemia—Thalidomide—leprosy	0.00109	0.00635	CcSEcCtD
Nilotinib—Hearing impaired—Thalidomide—leprosy	0.00108	0.00631	CcSEcCtD
Nilotinib—Creatinine increased—Thalidomide—leprosy	0.00108	0.00631	CcSEcCtD
Nilotinib—Bone pain—Thalidomide—leprosy	0.00107	0.00627	CcSEcCtD
Nilotinib—Atrioventricular block—Thalidomide—leprosy	0.00106	0.0062	CcSEcCtD
Nilotinib—Blood uric acid increased—Thalidomide—leprosy	0.00105	0.00612	CcSEcCtD
Nilotinib—Neck pain—Thalidomide—leprosy	0.00104	0.00608	CcSEcCtD
Nilotinib—Phosphatase alkaline increased—Thalidomide—leprosy	0.00103	0.00601	CcSEcCtD
Nilotinib—HCK—tendon—leprosy	0.00102	0.00741	CbGeAlD
Nilotinib—ABL2—tendon—leprosy	0.00102	0.00736	CbGeAlD
Nilotinib—MAP4K1—testis—leprosy	0.00102	0.00735	CbGeAlD
Nilotinib—LYN—nervous system—leprosy	0.00101	0.00733	CbGeAlD
Nilotinib—Hyperkalaemia—Thalidomide—leprosy	0.00101	0.0059	CcSEcCtD
Nilotinib—Pharyngitis—Dapsone—leprosy	0.001	0.00585	CcSEcCtD
Nilotinib—CA12—eye—leprosy	0.000984	0.00711	CbGeAlD
Nilotinib—Skin exfoliation—Thalidomide—leprosy	0.000981	0.00574	CcSEcCtD
Nilotinib—Candida infection—Thalidomide—leprosy	0.000981	0.00574	CcSEcCtD
Nilotinib—EPHB6—skin of body—leprosy	0.000978	0.00707	CbGeAlD
Nilotinib—TIE1—testis—leprosy	0.000971	0.00702	CbGeAlD
Nilotinib—Blood urea increased—Thalidomide—leprosy	0.00097	0.00567	CcSEcCtD
Nilotinib—TIE1—nervous system—leprosy	0.000953	0.00689	CbGeAlD
Nilotinib—Dry eye—Thalidomide—leprosy	0.000949	0.00555	CcSEcCtD
Nilotinib—Tinnitus—Dapsone—leprosy	0.00094	0.0055	CcSEcCtD
Nilotinib—CSF1R—eye—leprosy	0.000938	0.00678	CbGeAlD
Nilotinib—EPHA4—tendon—leprosy	0.000931	0.00673	CbGeAlD
Nilotinib—BRAF—testis—leprosy	0.000931	0.00673	CbGeAlD
Nilotinib—EPHB3—testis—leprosy	0.000923	0.00667	CbGeAlD
Nilotinib—CA3—tendon—leprosy	0.00092	0.00665	CbGeAlD
Nilotinib—Gynaecomastia—Thalidomide—leprosy	0.00092	0.00538	CcSEcCtD
Nilotinib—Pulmonary oedema—Thalidomide—leprosy	0.000915	0.00535	CcSEcCtD
Nilotinib—EPHB3—nervous system—leprosy	0.000906	0.00655	CbGeAlD
Nilotinib—Sepsis—Thalidomide—leprosy	0.000892	0.00522	CcSEcCtD
Nilotinib—CA9—tendon—leprosy	0.000881	0.00637	CbGeAlD
Nilotinib—Erythema—Dapsone—leprosy	0.000878	0.00513	CcSEcCtD
Nilotinib—MAPK14—tendon—leprosy	0.000859	0.00621	CbGeAlD
Nilotinib—Diabetes mellitus—Thalidomide—leprosy	0.000858	0.00502	CcSEcCtD
Nilotinib—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.000858	0.00502	CcSEcCtD
Nilotinib—FGR—tendon—leprosy	0.000855	0.00618	CbGeAlD
Nilotinib—Photosensitivity—Thalidomide—leprosy	0.00085	0.00497	CcSEcCtD
Nilotinib—HCK—testis—leprosy	0.000848	0.00613	CbGeAlD
Nilotinib—ABL2—testis—leprosy	0.000843	0.00609	CbGeAlD
Nilotinib—Gastroenteritis—Thalidomide—leprosy	0.000842	0.00492	CcSEcCtD
Nilotinib—CA14—tendon—leprosy	0.000835	0.00604	CbGeAlD
Nilotinib—Deafness—Thalidomide—leprosy	0.000834	0.00488	CcSEcCtD
Nilotinib—HCK—nervous system—leprosy	0.000833	0.00602	CbGeAlD
Nilotinib—PDGFRB—eye—leprosy	0.000832	0.00601	CbGeAlD
Nilotinib—Eczema—Thalidomide—leprosy	0.00083	0.00485	CcSEcCtD
Nilotinib—Vision blurred—Dapsone—leprosy	0.000827	0.00484	CcSEcCtD
Nilotinib—Eye pain—Thalidomide—leprosy	0.000826	0.00483	CcSEcCtD
Nilotinib—CSF1R—skin of body—leprosy	0.000816	0.0059	CbGeAlD
Nilotinib—EPHB4—tendon—leprosy	0.000814	0.00588	CbGeAlD
Nilotinib—EPHA2—tendon—leprosy	0.000798	0.00577	CbGeAlD
Nilotinib—Increased appetite—Thalidomide—leprosy	0.000794	0.00464	CcSEcCtD
Nilotinib—Amnesia—Thalidomide—leprosy	0.000794	0.00464	CcSEcCtD
Nilotinib—Vertigo—Dapsone—leprosy	0.000789	0.00461	CcSEcCtD
Nilotinib—Atrial fibrillation—Thalidomide—leprosy	0.000787	0.0046	CcSEcCtD
Nilotinib—Dermatitis bullous—Thalidomide—leprosy	0.000781	0.00456	CcSEcCtD
Nilotinib—CA1—eye—leprosy	0.000779	0.00563	CbGeAlD
Nilotinib—TEK—tendon—leprosy	0.000779	0.00563	CbGeAlD
Nilotinib—EPHA4—testis—leprosy	0.000771	0.00557	CbGeAlD
Nilotinib—Arthritis—Thalidomide—leprosy	0.000768	0.00449	CcSEcCtD
Nilotinib—Cough—Dapsone—leprosy	0.000766	0.00448	CcSEcCtD
Nilotinib—Cardiac failure—Thalidomide—leprosy	0.000764	0.00447	CcSEcCtD
Nilotinib—Hypoglycaemia—Thalidomide—leprosy	0.000764	0.00447	CcSEcCtD
Nilotinib—CA3—testis—leprosy	0.000762	0.00551	CbGeAlD
Nilotinib—Lethargy—Thalidomide—leprosy	0.000761	0.00445	CcSEcCtD
Nilotinib—EPHA4—nervous system—leprosy	0.000757	0.00547	CbGeAlD
Nilotinib—Hyponatraemia—Thalidomide—leprosy	0.000749	0.00438	CcSEcCtD
Nilotinib—CA3—nervous system—leprosy	0.000747	0.0054	CbGeAlD
Nilotinib—Pain in extremity—Thalidomide—leprosy	0.000746	0.00436	CcSEcCtD
Nilotinib—Diplopia—Thalidomide—leprosy	0.000746	0.00436	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Thalidomide—leprosy	0.000746	0.00436	CcSEcCtD
Nilotinib—EPHB6—tendon—leprosy	0.000744	0.00538	CbGeAlD
Nilotinib—ABL1—eye—leprosy	0.000742	0.00536	CbGeAlD
Nilotinib—KIT—skin of body—leprosy	0.000741	0.00536	CbGeAlD
Nilotinib—Migraine—Thalidomide—leprosy	0.000734	0.00429	CcSEcCtD
Nilotinib—CA9—testis—leprosy	0.000729	0.00527	CbGeAlD
Nilotinib—PDGFRB—skin of body—leprosy	0.000724	0.00523	CbGeAlD
Nilotinib—Face oedema—Thalidomide—leprosy	0.00072	0.00421	CcSEcCtD
Nilotinib—MAPK14—testis—leprosy	0.000711	0.00514	CbGeAlD
Nilotinib—LCK—testis—leprosy	0.000708	0.00512	CbGeAlD
Nilotinib—FGR—testis—leprosy	0.000708	0.00512	CbGeAlD
Nilotinib—PDGFRA—tendon—leprosy	0.000706	0.0051	CbGeAlD
Nilotinib—Tachycardia—Dapsone—leprosy	0.000699	0.00409	CcSEcCtD
Nilotinib—Blood creatinine increased—Thalidomide—leprosy	0.000699	0.00409	CcSEcCtD
Nilotinib—MAPK14—nervous system—leprosy	0.000698	0.00504	CbGeAlD
Nilotinib—FGR—nervous system—leprosy	0.000695	0.00502	CbGeAlD
Nilotinib—Dehydration—Thalidomide—leprosy	0.000694	0.00406	CcSEcCtD
Nilotinib—Dry skin—Thalidomide—leprosy	0.000684	0.004	CcSEcCtD
Nilotinib—Hypokalaemia—Thalidomide—leprosy	0.000679	0.00397	CcSEcCtD
Nilotinib—Breast disorder—Thalidomide—leprosy	0.000674	0.00394	CcSEcCtD
Nilotinib—EPHB4—testis—leprosy	0.000674	0.00487	CbGeAlD
Nilotinib—Aspartate aminotransferase increased—Thalidomide—leprosy	0.000672	0.00393	CcSEcCtD
Nilotinib—EPHA2—testis—leprosy	0.000661	0.00478	CbGeAlD
Nilotinib—Muscular weakness—Thalidomide—leprosy	0.000658	0.00385	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Thalidomide—leprosy	0.000658	0.00385	CcSEcCtD
Nilotinib—Abdominal distension—Thalidomide—leprosy	0.000649	0.0038	CcSEcCtD
Nilotinib—EPHA2—nervous system—leprosy	0.000649	0.00469	CbGeAlD
Nilotinib—Insomnia—Dapsone—leprosy	0.000648	0.00379	CcSEcCtD
Nilotinib—ABL1—skin of body—leprosy	0.000645	0.00466	CbGeAlD
Nilotinib—TEK—testis—leprosy	0.000645	0.00466	CbGeAlD
Nilotinib—Influenza—Thalidomide—leprosy	0.000645	0.00377	CcSEcCtD
Nilotinib—Eosinophilia—Thalidomide—leprosy	0.000638	0.00373	CcSEcCtD
Nilotinib—MAP2K5—tendon—leprosy	0.000637	0.0046	CbGeAlD
Nilotinib—TEK—nervous system—leprosy	0.000633	0.00458	CbGeAlD
Nilotinib—Pancreatitis—Thalidomide—leprosy	0.000632	0.0037	CcSEcCtD
Nilotinib—Angina pectoris—Thalidomide—leprosy	0.000628	0.00367	CcSEcCtD
Nilotinib—CSF1R—tendon—leprosy	0.000621	0.00449	CbGeAlD
Nilotinib—Bronchitis—Thalidomide—leprosy	0.00062	0.00363	CcSEcCtD
Nilotinib—EPHB6—testis—leprosy	0.000616	0.00446	CbGeAlD
Nilotinib—Pancytopenia—Thalidomide—leprosy	0.000612	0.00358	CcSEcCtD
Nilotinib—EPHB6—nervous system—leprosy	0.000605	0.00437	CbGeAlD
Nilotinib—Neutropenia—Thalidomide—leprosy	0.000603	0.00353	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Thalidomide—leprosy	0.000599	0.0035	CcSEcCtD
Nilotinib—Pollakiuria—Thalidomide—leprosy	0.000596	0.00348	CcSEcCtD
Nilotinib—Erectile dysfunction—Thalidomide—leprosy	0.000594	0.00347	CcSEcCtD
Nilotinib—Photosensitivity reaction—Thalidomide—leprosy	0.000589	0.00344	CcSEcCtD
Nilotinib—Weight increased—Thalidomide—leprosy	0.000587	0.00343	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dapsone—leprosy	0.000586	0.00343	CcSEcCtD
Nilotinib—PDGFRA—testis—leprosy	0.000584	0.00422	CbGeAlD
Nilotinib—Weight decreased—Thalidomide—leprosy	0.000583	0.00341	CcSEcCtD
Nilotinib—Hyperglycaemia—Thalidomide—leprosy	0.000582	0.0034	CcSEcCtD
Nilotinib—Pneumonia—Thalidomide—leprosy	0.000578	0.00338	CcSEcCtD
Nilotinib—Infestation—Thalidomide—leprosy	0.000575	0.00336	CcSEcCtD
Nilotinib—Infestation NOS—Thalidomide—leprosy	0.000575	0.00336	CcSEcCtD
Nilotinib—PDGFRA—nervous system—leprosy	0.000573	0.00415	CbGeAlD
Nilotinib—Acute coronary syndrome—Thalidomide—leprosy	0.000567	0.00331	CcSEcCtD
Nilotinib—Abdominal pain—Dapsone—leprosy	0.000566	0.00331	CcSEcCtD
Nilotinib—Body temperature increased—Dapsone—leprosy	0.000566	0.00331	CcSEcCtD
Nilotinib—Renal failure—Thalidomide—leprosy	0.000565	0.0033	CcSEcCtD
Nilotinib—Neuropathy peripheral—Thalidomide—leprosy	0.000564	0.0033	CcSEcCtD
Nilotinib—Myocardial infarction—Thalidomide—leprosy	0.000564	0.0033	CcSEcCtD
Nilotinib—Stomatitis—Thalidomide—leprosy	0.00056	0.00328	CcSEcCtD
Nilotinib—Conjunctivitis—Thalidomide—leprosy	0.000559	0.00327	CcSEcCtD
Nilotinib—PDGFRB—tendon—leprosy	0.000551	0.00398	CbGeAlD
Nilotinib—Haematuria—Thalidomide—leprosy	0.000548	0.00321	CcSEcCtD
Nilotinib—Epistaxis—Thalidomide—leprosy	0.000542	0.00317	CcSEcCtD
Nilotinib—CA12—nervous system—leprosy	0.000529	0.00383	CbGeAlD
Nilotinib—MAP2K5—testis—leprosy	0.000527	0.00381	CbGeAlD
Nilotinib—Bradycardia—Thalidomide—leprosy	0.000525	0.00307	CcSEcCtD
Nilotinib—Rhinitis—Thalidomide—leprosy	0.000517	0.00303	CcSEcCtD
Nilotinib—MAP2K5—nervous system—leprosy	0.000517	0.00374	CbGeAlD
Nilotinib—Hepatitis—Thalidomide—leprosy	0.000516	0.00302	CcSEcCtD
Nilotinib—CSF1R—testis—leprosy	0.000514	0.00372	CbGeAlD
Nilotinib—Hypoaesthesia—Thalidomide—leprosy	0.000514	0.003	CcSEcCtD
Nilotinib—Pharyngitis—Thalidomide—leprosy	0.000512	0.003	CcSEcCtD
Nilotinib—Urinary tract disorder—Thalidomide—leprosy	0.00051	0.00298	CcSEcCtD
Nilotinib—Oedema peripheral—Thalidomide—leprosy	0.000508	0.00297	CcSEcCtD
Nilotinib—Urethral disorder—Thalidomide—leprosy	0.000506	0.00296	CcSEcCtD
Nilotinib—CA2—eye—leprosy	0.000505	0.00365	CbGeAlD
Nilotinib—CSF1R—nervous system—leprosy	0.000505	0.00365	CbGeAlD
Nilotinib—Visual impairment—Thalidomide—leprosy	0.000497	0.00291	CcSEcCtD
Nilotinib—ABL1—tendon—leprosy	0.000491	0.00355	CbGeAlD
Nilotinib—Erythema multiforme—Thalidomide—leprosy	0.000488	0.00285	CcSEcCtD
Nilotinib—Eye disorder—Thalidomide—leprosy	0.000482	0.00282	CcSEcCtD
Nilotinib—Tinnitus—Thalidomide—leprosy	0.000481	0.00281	CcSEcCtD
Nilotinib—Cardiac disorder—Thalidomide—leprosy	0.000479	0.0028	CcSEcCtD
Nilotinib—Angiopathy—Thalidomide—leprosy	0.000468	0.00274	CcSEcCtD
Nilotinib—KIT—testis—leprosy	0.000467	0.00338	CbGeAlD
Nilotinib—Immune system disorder—Thalidomide—leprosy	0.000466	0.00273	CcSEcCtD
Nilotinib—Mediastinal disorder—Thalidomide—leprosy	0.000465	0.00272	CcSEcCtD
Nilotinib—Chills—Thalidomide—leprosy	0.000463	0.00271	CcSEcCtD
Nilotinib—Arrhythmia—Thalidomide—leprosy	0.000461	0.0027	CcSEcCtD
Nilotinib—KIT—nervous system—leprosy	0.000458	0.00331	CbGeAlD
Nilotinib—PDGFRB—testis—leprosy	0.000456	0.0033	CbGeAlD
Nilotinib—Alopecia—Thalidomide—leprosy	0.000456	0.00267	CcSEcCtD
Nilotinib—Vomiting—Dapsone—leprosy	0.000455	0.00266	CcSEcCtD
Nilotinib—Mental disorder—Thalidomide—leprosy	0.000452	0.00264	CcSEcCtD
Nilotinib—Malnutrition—Thalidomide—leprosy	0.000449	0.00263	CcSEcCtD
Nilotinib—Headache—Dapsone—leprosy	0.000449	0.00262	CcSEcCtD
Nilotinib—PDGFRB—nervous system—leprosy	0.000448	0.00324	CbGeAlD
Nilotinib—Flatulence—Thalidomide—leprosy	0.000443	0.00259	CcSEcCtD
Nilotinib—Dysgeusia—Thalidomide—leprosy	0.00044	0.00257	CcSEcCtD
Nilotinib—CA2—skin of body—leprosy	0.000439	0.00318	CbGeAlD
Nilotinib—Back pain—Thalidomide—leprosy	0.000435	0.00254	CcSEcCtD
Nilotinib—ABCB1—blood vessel—leprosy	0.000433	0.00313	CbGeAlD
Nilotinib—Muscle spasms—Thalidomide—leprosy	0.000432	0.00253	CcSEcCtD
Nilotinib—Nausea—Dapsone—leprosy	0.000425	0.00249	CcSEcCtD
Nilotinib—Vision blurred—Thalidomide—leprosy	0.000423	0.00248	CcSEcCtD
Nilotinib—Tremor—Thalidomide—leprosy	0.000421	0.00246	CcSEcCtD
Nilotinib—CA1—nervous system—leprosy	0.000419	0.00303	CbGeAlD
Nilotinib—Ill-defined disorder—Thalidomide—leprosy	0.000417	0.00244	CcSEcCtD
Nilotinib—Anaemia—Thalidomide—leprosy	0.000415	0.00243	CcSEcCtD
Nilotinib—ABL1—testis—leprosy	0.000407	0.00294	CbGeAlD
Nilotinib—Malaise—Thalidomide—leprosy	0.000405	0.00237	CcSEcCtD
Nilotinib—Vertigo—Thalidomide—leprosy	0.000404	0.00236	CcSEcCtD
Nilotinib—CA4—tendon—leprosy	0.000403	0.00292	CbGeAlD
Nilotinib—Syncope—Thalidomide—leprosy	0.000403	0.00236	CcSEcCtD
Nilotinib—Leukopenia—Thalidomide—leprosy	0.000402	0.00235	CcSEcCtD
Nilotinib—ABL1—nervous system—leprosy	0.000399	0.00289	CbGeAlD
Nilotinib—Palpitations—Thalidomide—leprosy	0.000397	0.00232	CcSEcCtD
Nilotinib—Loss of consciousness—Thalidomide—leprosy	0.000395	0.00231	CcSEcCtD
Nilotinib—Cough—Thalidomide—leprosy	0.000392	0.00229	CcSEcCtD
Nilotinib—Hypertension—Thalidomide—leprosy	0.000388	0.00227	CcSEcCtD
Nilotinib—Chest pain—Thalidomide—leprosy	0.000382	0.00224	CcSEcCtD
Nilotinib—Arthralgia—Thalidomide—leprosy	0.000382	0.00224	CcSEcCtD
Nilotinib—Myalgia—Thalidomide—leprosy	0.000382	0.00224	CcSEcCtD
Nilotinib—Anxiety—Thalidomide—leprosy	0.000381	0.00223	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00038	0.00222	CcSEcCtD
Nilotinib—Discomfort—Thalidomide—leprosy	0.000378	0.00221	CcSEcCtD
Nilotinib—CYP2B6—skin of body—leprosy	0.000375	0.00271	CbGeAlD
Nilotinib—Dry mouth—Thalidomide—leprosy	0.000374	0.00219	CcSEcCtD
Nilotinib—Confusional state—Thalidomide—leprosy	0.00037	0.00216	CcSEcCtD
Nilotinib—Oedema—Thalidomide—leprosy	0.000367	0.00214	CcSEcCtD
Nilotinib—Infection—Thalidomide—leprosy	0.000364	0.00213	CcSEcCtD
Nilotinib—Shock—Thalidomide—leprosy	0.000361	0.00211	CcSEcCtD
Nilotinib—Nervous system disorder—Thalidomide—leprosy	0.00036	0.0021	CcSEcCtD
Nilotinib—Thrombocytopenia—Thalidomide—leprosy	0.000359	0.0021	CcSEcCtD
Nilotinib—Tachycardia—Thalidomide—leprosy	0.000358	0.00209	CcSEcCtD
Nilotinib—Skin disorder—Thalidomide—leprosy	0.000356	0.00208	CcSEcCtD
Nilotinib—Hyperhidrosis—Thalidomide—leprosy	0.000354	0.00207	CcSEcCtD
Nilotinib—Anorexia—Thalidomide—leprosy	0.00035	0.00204	CcSEcCtD
Nilotinib—Hypotension—Thalidomide—leprosy	0.000343	0.002	CcSEcCtD
Nilotinib—CA2—tendon—leprosy	0.000334	0.00242	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Thalidomide—leprosy	0.000334	0.00195	CcSEcCtD
Nilotinib—CA4—testis—leprosy	0.000334	0.00241	CbGeAlD
Nilotinib—Insomnia—Thalidomide—leprosy	0.000332	0.00194	CcSEcCtD
Nilotinib—Paraesthesia—Thalidomide—leprosy	0.000329	0.00193	CcSEcCtD
Nilotinib—CA4—nervous system—leprosy	0.000328	0.00237	CbGeAlD
Nilotinib—Dyspnoea—Thalidomide—leprosy	0.000327	0.00191	CcSEcCtD
Nilotinib—Dyspepsia—Thalidomide—leprosy	0.000323	0.00189	CcSEcCtD
Nilotinib—Decreased appetite—Thalidomide—leprosy	0.000319	0.00186	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Thalidomide—leprosy	0.000317	0.00185	CcSEcCtD
Nilotinib—Fatigue—Thalidomide—leprosy	0.000316	0.00185	CcSEcCtD
Nilotinib—Constipation—Thalidomide—leprosy	0.000314	0.00183	CcSEcCtD
Nilotinib—Pain—Thalidomide—leprosy	0.000314	0.00183	CcSEcCtD
Nilotinib—Feeling abnormal—Thalidomide—leprosy	0.000302	0.00177	CcSEcCtD
Nilotinib—Gastrointestinal pain—Thalidomide—leprosy	0.0003	0.00175	CcSEcCtD
Nilotinib—Urticaria—Thalidomide—leprosy	0.000291	0.0017	CcSEcCtD
Nilotinib—Body temperature increased—Thalidomide—leprosy	0.00029	0.0017	CcSEcCtD
Nilotinib—Abdominal pain—Thalidomide—leprosy	0.00029	0.0017	CcSEcCtD
Nilotinib—CA2—testis—leprosy	0.000277	0.002	CbGeAlD
Nilotinib—CA2—nervous system—leprosy	0.000272	0.00196	CbGeAlD
Nilotinib—Hypersensitivity—Thalidomide—leprosy	0.00027	0.00158	CcSEcCtD
Nilotinib—CYP2C8—testis—leprosy	0.000264	0.00191	CbGeAlD
Nilotinib—Asthenia—Thalidomide—leprosy	0.000263	0.00154	CcSEcCtD
Nilotinib—Pruritus—Thalidomide—leprosy	0.000259	0.00152	CcSEcCtD
Nilotinib—ABCG2—testis—leprosy	0.000256	0.00185	CbGeAlD
Nilotinib—Diarrhoea—Thalidomide—leprosy	0.000251	0.00147	CcSEcCtD
Nilotinib—Dizziness—Thalidomide—leprosy	0.000242	0.00142	CcSEcCtD
Nilotinib—CYP2B6—testis—leprosy	0.000237	0.00171	CbGeAlD
Nilotinib—Vomiting—Thalidomide—leprosy	0.000233	0.00136	CcSEcCtD
Nilotinib—CYP2B6—nervous system—leprosy	0.000232	0.00168	CbGeAlD
Nilotinib—Rash—Thalidomide—leprosy	0.000231	0.00135	CcSEcCtD
Nilotinib—Dermatitis—Thalidomide—leprosy	0.000231	0.00135	CcSEcCtD
Nilotinib—Headache—Thalidomide—leprosy	0.00023	0.00134	CcSEcCtD
Nilotinib—Nausea—Thalidomide—leprosy	0.000218	0.00127	CcSEcCtD
Nilotinib—CYP2D6—testis—leprosy	0.000176	0.00127	CbGeAlD
Nilotinib—CYP3A4—nervous system—leprosy	0.000175	0.00127	CbGeAlD
Nilotinib—CYP2D6—nervous system—leprosy	0.000173	0.00125	CbGeAlD
Nilotinib—ABCB1—testis—leprosy	0.000126	0.000914	CbGeAlD
Nilotinib—ABCB1—nervous system—leprosy	0.000124	0.000897	CbGeAlD
Nilotinib—EPHB3—Developmental Biology—TNF—leprosy	7.97e-05	0.000521	CbGpPWpGaD
Nilotinib—BRAF—MAPK Signaling Pathway—TNF—leprosy	7.85e-05	0.000514	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—NOD2—leprosy	7.84e-05	0.000513	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CYLD—leprosy	7.81e-05	0.000511	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—RIPK2—leprosy	7.79e-05	0.000509	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—TLR2—leprosy	7.79e-05	0.000509	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—RIPK2—leprosy	7.63e-05	0.000499	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—TLR2—leprosy	7.63e-05	0.000499	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—RIPK2—leprosy	7.59e-05	0.000496	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—TLR2—leprosy	7.59e-05	0.000496	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—HLA-DRB1—leprosy	7.53e-05	0.000493	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—RIPK2—leprosy	7.48e-05	0.000489	CbGpPWpGaD
Nilotinib—HCK—Immune System—NOD2—leprosy	7.41e-05	0.000485	CbGpPWpGaD
Nilotinib—BLK—Immune System—RIPK2—leprosy	7.4e-05	0.000484	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—RIPK2—leprosy	7.4e-05	0.000484	CbGpPWpGaD
Nilotinib—BLK—Immune System—TLR2—leprosy	7.4e-05	0.000484	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—TLR2—leprosy	7.4e-05	0.000484	CbGpPWpGaD
Nilotinib—BRAF—Disease—SLC11A1—leprosy	7.4e-05	0.000484	CbGpPWpGaD
Nilotinib—FGR—Immune System—TLR2—leprosy	7.38e-05	0.000483	CbGpPWpGaD
Nilotinib—FGR—Immune System—RIPK2—leprosy	7.38e-05	0.000483	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—RIPK2—leprosy	7.32e-05	0.000479	CbGpPWpGaD
Nilotinib—KIT—Immune System—PARK2—leprosy	7.3e-05	0.000477	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IFNG—leprosy	7.24e-05	0.000474	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—RIPK2—leprosy	7.23e-05	0.000473	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—TLR2—leprosy	7.23e-05	0.000473	CbGpPWpGaD
Nilotinib—EPHA3—Developmental Biology—TNF—leprosy	7.1e-05	0.000464	CbGpPWpGaD
Nilotinib—ABL2—Developmental Biology—TNF—leprosy	7.1e-05	0.000464	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—NOD2—leprosy	7.06e-05	0.000462	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CYLD—leprosy	7.04e-05	0.00046	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—NOD2—leprosy	6.91e-05	0.000452	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PARK2—leprosy	6.91e-05	0.000452	CbGpPWpGaD
Nilotinib—LYN—Immune System—CYLD—leprosy	6.89e-05	0.000451	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—NOD2—leprosy	6.88e-05	0.00045	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—leprosy	6.88e-05	0.00045	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CYLD—leprosy	6.86e-05	0.000449	CbGpPWpGaD
Nilotinib—EPHA8—Developmental Biology—TNF—leprosy	6.85e-05	0.000448	CbGpPWpGaD
Nilotinib—EPHB4—Developmental Biology—TNF—leprosy	6.77e-05	0.000443	CbGpPWpGaD
Nilotinib—EPHA4—Developmental Biology—TNF—leprosy	6.77e-05	0.000443	CbGpPWpGaD
Nilotinib—KIT—Disease—SLC11A1—leprosy	6.74e-05	0.000441	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD40LG—leprosy	6.72e-05	0.00044	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—NOD2—leprosy	6.71e-05	0.000439	CbGpPWpGaD
Nilotinib—BLK—Immune System—NOD2—leprosy	6.71e-05	0.000439	CbGpPWpGaD
Nilotinib—FGR—Immune System—NOD2—leprosy	6.69e-05	0.000438	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD8A—leprosy	6.65e-05	0.000435	CbGpPWpGaD
Nilotinib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—leprosy	6.59e-05	0.000431	CbGpPWpGaD
Nilotinib—LYN—Platelet activation, signaling and aggregation—IL2—leprosy	6.58e-05	0.00043	CbGpPWpGaD
Nilotinib—EPHB2—Developmental Biology—TNF—leprosy	6.56e-05	0.000429	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—NOD2—leprosy	6.55e-05	0.000429	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CYLD—leprosy	6.53e-05	0.000427	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IL2—leprosy	6.43e-05	0.000421	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SLC11A1—leprosy	6.38e-05	0.000417	CbGpPWpGaD
Nilotinib—EPHB6—Developmental Biology—TNF—leprosy	6.37e-05	0.000417	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD40LG—leprosy	6.36e-05	0.000416	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD8A—leprosy	6.29e-05	0.000412	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD40LG—leprosy	6.26e-05	0.00041	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—RIPK2—leprosy	6.25e-05	0.000409	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—TLR2—leprosy	6.25e-05	0.000409	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—IL2—leprosy	6.24e-05	0.000408	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PARK2—leprosy	6.22e-05	0.000407	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD8A—leprosy	6.19e-05	0.000405	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IFNG—leprosy	6.13e-05	0.000401	CbGpPWpGaD
Nilotinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—leprosy	6.11e-05	0.000399	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—CD4—leprosy	6.11e-05	0.000399	CbGpPWpGaD
Nilotinib—PDGFRB—MAPK Signaling Pathway—TNF—leprosy	6.1e-05	0.000399	CbGpPWpGaD
Nilotinib—LYN—Immune System—PARK2—leprosy	6.09e-05	0.000399	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PARK2—leprosy	6.06e-05	0.000397	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—RIPK2—leprosy	6e-05	0.000393	CbGpPWpGaD
Nilotinib—EPHA6—Developmental Biology—TNF—leprosy	5.99e-05	0.000392	CbGpPWpGaD
Nilotinib—LCK—HIV Infection—CD4—leprosy	5.97e-05	0.000391	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—RIPK2—leprosy	5.9e-05	0.000386	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—TLR2—leprosy	5.9e-05	0.000386	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—SDHD—leprosy	5.87e-05	0.000384	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PARK2—leprosy	5.78e-05	0.000378	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SLC11A1—leprosy	5.75e-05	0.000376	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD40LG—leprosy	5.73e-05	0.000375	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD40LG—leprosy	5.68e-05	0.000371	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD40LG—leprosy	5.68e-05	0.000371	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD8A—leprosy	5.67e-05	0.000371	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NOD2—leprosy	5.67e-05	0.000371	CbGpPWpGaD
Nilotinib—MAPK14—MAPK Signaling Pathway—TNF—leprosy	5.66e-05	0.00037	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD40LG—leprosy	5.66e-05	0.00037	CbGpPWpGaD
Nilotinib—LCK—Immune System—CYLD—leprosy	5.65e-05	0.00037	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—IL2—leprosy	5.64e-05	0.000369	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD40LG—leprosy	5.61e-05	0.000367	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD8A—leprosy	5.61e-05	0.000367	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD8A—leprosy	5.61e-05	0.000367	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD8A—leprosy	5.59e-05	0.000366	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD8A—leprosy	5.55e-05	0.000363	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—CD4—leprosy	5.53e-05	0.000362	CbGpPWpGaD
Nilotinib—EPHA2—Developmental Biology—TNF—leprosy	5.52e-05	0.000361	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—CD4—leprosy	5.52e-05	0.000361	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IL2—leprosy	5.45e-05	0.000356	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HLA-DRB1—leprosy	5.41e-05	0.000354	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—IL2—leprosy	5.39e-05	0.000353	CbGpPWpGaD
Nilotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	5.36e-05	0.000351	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NOD2—leprosy	5.35e-05	0.00035	CbGpPWpGaD
Nilotinib—KIT—Immune System—TLR2—leprosy	5.32e-05	0.000348	CbGpPWpGaD
Nilotinib—KIT—Immune System—RIPK2—leprosy	5.32e-05	0.000348	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—CD4—leprosy	5.31e-05	0.000348	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HLA-DRB1—leprosy	5.12e-05	0.000335	CbGpPWpGaD
Nilotinib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—leprosy	5.11e-05	0.000334	CbGpPWpGaD
Nilotinib—HCK—Immune System—HLA-DRB1—leprosy	5.04e-05	0.00033	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—RIPK2—leprosy	5.04e-05	0.000329	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—TLR2—leprosy	5.04e-05	0.000329	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IFNG—leprosy	5.02e-05	0.000329	CbGpPWpGaD
Nilotinib—LCK—Immune System—PARK2—leprosy	4.99e-05	0.000327	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—SDHD—leprosy	4.98e-05	0.000326	CbGpPWpGaD
Nilotinib—KIT—Immune System—NOD2—leprosy	4.82e-05	0.000315	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—RIPK2—leprosy	4.79e-05	0.000313	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—TNF—leprosy	4.69e-05	0.000307	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HLA-DRB1—leprosy	4.62e-05	0.000302	CbGpPWpGaD
Nilotinib—LCK—Disease—SLC11A1—leprosy	4.61e-05	0.000302	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD40LG—leprosy	4.6e-05	0.000301	CbGpPWpGaD
Nilotinib—BLK—Immune System—HLA-DRB1—leprosy	4.57e-05	0.000299	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HLA-DRB1—leprosy	4.57e-05	0.000299	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NOD2—leprosy	4.57e-05	0.000299	CbGpPWpGaD
Nilotinib—FGR—Immune System—HLA-DRB1—leprosy	4.55e-05	0.000298	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RIPK2—leprosy	4.55e-05	0.000298	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD8A—leprosy	4.55e-05	0.000298	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—RIPK2—leprosy	4.54e-05	0.000297	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—TLR2—leprosy	4.54e-05	0.000297	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD40LG—leprosy	4.52e-05	0.000296	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HLA-DRB1—leprosy	4.52e-05	0.000296	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD8A—leprosy	4.47e-05	0.000292	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL2—leprosy	4.46e-05	0.000292	CbGpPWpGaD
Nilotinib—LYN—Immune System—TLR2—leprosy	4.44e-05	0.00029	CbGpPWpGaD
Nilotinib—LYN—Immune System—RIPK2—leprosy	4.44e-05	0.00029	CbGpPWpGaD
Nilotinib—ABL1—Immune System—RIPK2—leprosy	4.42e-05	0.000289	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TLR2—leprosy	4.42e-05	0.000289	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—CD4—leprosy	4.41e-05	0.000288	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC11A1—leprosy	4.32e-05	0.000282	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—RIPK2—leprosy	4.21e-05	0.000275	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TLR2—leprosy	4.21e-05	0.000275	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NOD2—leprosy	4.11e-05	0.000269	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD40LG—leprosy	4.08e-05	0.000267	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD8A—leprosy	4.03e-05	0.000264	CbGpPWpGaD
Nilotinib—LYN—Immune System—NOD2—leprosy	4.03e-05	0.000263	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NOD2—leprosy	4.01e-05	0.000262	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—CD4—leprosy	3.98e-05	0.00026	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD40LG—leprosy	3.86e-05	0.000252	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—CD4—leprosy	3.82e-05	0.00025	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NOD2—leprosy	3.82e-05	0.00025	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD8A—leprosy	3.82e-05	0.00025	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RIPK2—leprosy	3.81e-05	0.000249	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RIPK2—leprosy	3.78e-05	0.000247	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—CD4—leprosy	3.76e-05	0.000246	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HLA-DRB1—leprosy	3.7e-05	0.000242	CbGpPWpGaD
Nilotinib—HCK—Immune System—IFNG—leprosy	3.68e-05	0.000241	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SDHD—leprosy	3.65e-05	0.000239	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HLA-DRB1—leprosy	3.64e-05	0.000238	CbGpPWpGaD
Nilotinib—LCK—Immune System—RIPK2—leprosy	3.64e-05	0.000238	CbGpPWpGaD
Nilotinib—LCK—Immune System—TLR2—leprosy	3.64e-05	0.000238	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—CD4—leprosy	3.61e-05	0.000236	CbGpPWpGaD
Nilotinib—HCK—Immune System—CD4—leprosy	3.56e-05	0.000233	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD40LG—leprosy	3.48e-05	0.000227	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RIPK2—leprosy	3.44e-05	0.000225	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD8A—leprosy	3.44e-05	0.000225	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD40LG—leprosy	3.4e-05	0.000223	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—IL2—leprosy	3.39e-05	0.000222	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—CD4—leprosy	3.39e-05	0.000222	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD40LG—leprosy	3.39e-05	0.000222	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—IL2—leprosy	3.38e-05	0.000221	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD8A—leprosy	3.37e-05	0.00022	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD8A—leprosy	3.35e-05	0.000219	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—TNF—leprosy	3.35e-05	0.000219	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IFNG—leprosy	3.34e-05	0.000218	CbGpPWpGaD
Nilotinib—BLK—Immune System—IFNG—leprosy	3.34e-05	0.000218	CbGpPWpGaD
Nilotinib—FGR—Immune System—IFNG—leprosy	3.33e-05	0.000218	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—CD4—leprosy	3.32e-05	0.000217	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—CD4—leprosy	3.3e-05	0.000216	CbGpPWpGaD
Nilotinib—LCK—Immune System—NOD2—leprosy	3.3e-05	0.000216	CbGpPWpGaD
Nilotinib—HCK—Disease—CD4—leprosy	3.28e-05	0.000215	CbGpPWpGaD
Nilotinib—KIT—Immune System—HLA-DRB1—leprosy	3.28e-05	0.000215	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL2—leprosy	3.27e-05	0.000214	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RIPK2—leprosy	3.26e-05	0.000213	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—CD4—leprosy	3.26e-05	0.000213	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD40LG—leprosy	3.23e-05	0.000211	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD4—leprosy	3.22e-05	0.000211	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD4—leprosy	3.22e-05	0.000211	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IL2—leprosy	3.22e-05	0.00021	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD4—leprosy	3.21e-05	0.00021	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD8A—leprosy	3.19e-05	0.000209	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD4—leprosy	3.19e-05	0.000208	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CD4—leprosy	3.15e-05	0.000206	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HLA-DRB1—leprosy	3.11e-05	0.000203	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SDHD—leprosy	3.09e-05	0.000202	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL2—leprosy	2.97e-05	0.000194	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL2—leprosy	2.97e-05	0.000194	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL2—leprosy	2.96e-05	0.000193	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RIPK2—leprosy	2.93e-05	0.000192	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RIPK2—leprosy	2.87e-05	0.000188	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HLA-DRB1—leprosy	2.8e-05	0.000183	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD40LG—leprosy	2.79e-05	0.000182	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IL2—leprosy	2.78e-05	0.000182	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD8A—leprosy	2.76e-05	0.00018	CbGpPWpGaD
Nilotinib—LYN—Immune System—HLA-DRB1—leprosy	2.74e-05	0.000179	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HLA-DRB1—leprosy	2.73e-05	0.000178	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RIPK2—leprosy	2.72e-05	0.000178	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—leprosy	2.72e-05	0.000178	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SDHD—leprosy	2.69e-05	0.000176	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IFNG—leprosy	2.66e-05	0.000174	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—leprosy	2.61e-05	0.000171	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HLA-DRB1—leprosy	2.6e-05	0.00017	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—leprosy	2.57e-05	0.000168	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SDHD—leprosy	2.54e-05	0.000166	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—leprosy	2.52e-05	0.000165	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SDHD—leprosy	2.51e-05	0.000164	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—leprosy	2.51e-05	0.000164	CbGpPWpGaD
Nilotinib—KIT—Immune System—IFNG—leprosy	2.4e-05	0.000157	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—leprosy	2.39e-05	0.000156	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL2—leprosy	2.36e-05	0.000155	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RIPK2—leprosy	2.35e-05	0.000154	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—leprosy	2.35e-05	0.000154	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—leprosy	2.32e-05	0.000151	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—leprosy	2.31e-05	0.000151	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IFNG—leprosy	2.27e-05	0.000148	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-DRB1—leprosy	2.25e-05	0.000147	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—leprosy	2.19e-05	0.000143	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—leprosy	2.14e-05	0.00014	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—leprosy	2.13e-05	0.000139	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—leprosy	2.04e-05	0.000134	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—leprosy	2.02e-05	0.000132	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—leprosy	2.02e-05	0.000132	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—leprosy	2e-05	0.000131	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—leprosy	1.99e-05	0.00013	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—leprosy	1.97e-05	0.000129	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—leprosy	1.93e-05	0.000126	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—leprosy	1.92e-05	0.000126	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—leprosy	1.92e-05	0.000125	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—leprosy	1.9e-05	0.000124	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—leprosy	1.83e-05	0.00012	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—leprosy	1.82e-05	0.000119	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—leprosy	1.82e-05	0.000119	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—leprosy	1.82e-05	0.000119	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—leprosy	1.78e-05	0.000116	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—leprosy	1.77e-05	0.000116	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—leprosy	1.69e-05	0.00011	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SDHD—leprosy	1.66e-05	0.000108	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—leprosy	1.64e-05	0.000107	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—leprosy	1.58e-05	0.000104	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—leprosy	1.53e-05	9.99e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—leprosy	1.51e-05	9.9e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—leprosy	1.46e-05	9.57e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—leprosy	1.46e-05	9.54e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—leprosy	1.38e-05	9.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—leprosy	1.3e-05	8.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—leprosy	1.17e-05	7.68e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—leprosy	1.15e-05	7.52e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—leprosy	1.09e-05	7.13e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—leprosy	9.43e-06	6.17e-05	CbGpPWpGaD
